Effect of Ciprofol Injection on Postoperative Cognitive Function

NCT07673978 | Active Not Recruiting Phase 4

• 1 other identifier: 2026-166
• Study Type: interventional
• Target: 298
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to explore the effect of ciprofol on the postoperative cognitive function of inpatients undergoing gastrointestinal endoscopy examination, to compare the anesthetic effects and differences in adverse reactions of propofol and ciprofol in gastrointestinal endoscopy , to compare the incidence of postoperative cognitive decline in patients undergoing gastrointestinal endoscopy examination between propofol and coprofol, and to optimize the anesthesia medication regimen for patients undergoing gastrointestinal endoscopy examination.

Conditions

Postoperative Cognitive Dysfunction

Outcome Measures

Primary Outcomes (1)

• The difference in the incidence of cognitive function decline between ciprofol and propofol in patients undergoing painless gastroscopy and colonoscopy treatment

  From the time the patient was enrolled in the study to 24 hours after the treatment

Secondary Outcomes (5)

• Intraoperative and postoperative adverse events

  From the time the patient enters the operating room to 24 hours after the treatment

• Blood Pressure (mmHg)

  From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

• Heart Rate (beats/min)

  From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

• Respiratory Rate (breaths/min)

  From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

• Oxygen Saturation (Pulse Oximetry)

  From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

Other Outcomes (2)

• The dosage of propofol/ciprofol used

  The dosage of drugs used during this period from anesthesia induction to the end of anesthesia (perioperative period) (approximately 25 - 60 minutes)

• The patient's stay time in the PACU（Post-Anesthesia Care Unit）

  up to 24 hours

Study Arms (2)

Experimental group (ciprofol)

EXPERIMENTAL

patients in the Ciprofol group will use ciprofol to complete the painless gastroscopy and colonoscopy treatment.

Drug: Ciprofol group

Control group (propofol)

ACTIVE COMPARATOR

patients in the propofol group will use propofol to complete the painless gastroscopy and colonoscopy treatment.

Drug: Propofol group

Interventions

Ciprofol group DRUG

patients in the Ciprofol group will use ciprofol to complete the painless gastroscopy and colonoscopy treatment.

Experimental group (ciprofol)

Propofol group DRUG

patients in the propofol group will use propofol to complete the painless gastroscopy and colonoscopy treatment.

Control group (propofol)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18-65 years old, ASA grade I-Ⅲ, BMI index: 18.5-30 kg/m ²
• Patients who plan to undergo gastroscopy or colonoscopy in our hospital
• The preoperative assessment of the MOCA scale in patients scheduled for elective surgery indicated normal cognitive function
• dextromanuality
• Voluntarily participate in this study and sign the informed consent form

You may not qualify if:

• Pregnant or lactating women
• Patients who have had cardiovascular and cerebrovascular accidents in the past
• Patients with severe diseases of the cardiovascular system, respiratory system and liver and kidney system
• Patients with obstructive sleep apnea syndrome
• Patients with concurrent neurological or mental system diseases, or those with incomplete intellectual development
• Patients allergic to ciprofol or propofol drugs
• Patients with braking, visual/auditory impairments
• Patients with psychotropic drug addiction or alcohol dependence
• Patients who themselves or their attending physicians refused to participate in the study

Sponsors & Collaborators

• The Second Affiliated Hospital of Chongqing Medical University: lead

Study Sites (1)

The Second Affiliated Hospital Of Chongqing Medical University

Chongqing, Chongqing Municipality, 400010, China

Location

MeSH Terms

Conditions

Postoperative Cognitive Complications

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Cognitive Dysfunction; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Officials

• Guangyou Duan

  The Second Affiliated Hospital of Chongqing Medical University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: June 29, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: June 29, 2026

Record last verified: 2026-06

Locations

CN (1)